Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients

被引:273
作者
Hagemans, MLC
Winkel, LPF
Van Doorn, PA
Hop, WJC
Loonen, MCB
Reuser, AJJ
Van der Ploeg, AT
机构
[1] Erasmus MC Sophia, Dept Metab Dis & Genet, NL-3015 GJ Rotterdam, Netherlands
[2] Erasmus MC Sophia, Dept Child Neurol, NL-3015 GJ Rotterdam, Netherlands
[3] Erasmus MC, Dept Neurol, Rotterdam, Netherlands
[4] Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands
[5] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands
关键词
Pompe's disease; glycogen storage disease type II; alpha-glucosidase; acid maltase; natural course;
D O I
10.1093/brain/awh384
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Late-onset Pompe's disease (acid maltase deficiency, glycogen storage disease type II) is a slowly progressive myopathy caused by deficiency of acid alpha-glucosidase. Current developments in enzyme replacement therapy require detailed knowledge of the kind and severity of symptoms and the natural course of the disease in the patient population. A detailed questionnaire covering the patients' medical history and current situation was developed and information was gathered from 54 Dutch patients. The mean age of the participants was 48.6 +/- 15.6 years. The first complaints started at a mean age of 28.1 +/- 14.3 years and were mostly related to mobility problems and limb-girdle weakness. Fifty-eight percent of the adult patients indicated the presence of mild muscular symptoms during childhood. Twenty-eight percent of the patients waited >5 years for the final diagnosis after the first visit to a physician for disease-related complaints. At the time of questionnaire completion, 48% of the study population used a wheelchair and 37% used artificial ventilation. Movements such as rising from an armchair, taking stairs or getting upright after bending over were difficult or impossible for more than two-thirds of the respondents. The age at onset, the rate of disease progression and the sequence of respiratory and skeletal muscle involvement varied substantially between patients. Seventy-six percent of the participants indicated being troubled by fatigue and 46% by pain. This survey has mapped the age at onset, presenting symptoms, heterogeneity in progression and range of disease severity in a large group ofDutch patients. We conclude that early manifestations in childhood require proper attention to prevent unnecessary delay of the diagnosis. The follow-up of patients with late-onset Pompe's disease should focus on respiratory and limb-girdle muscle function, the capacity to perform daily activities, and the presentation of fatigue and pain.
引用
收藏
页码:671 / 677
页数:7
相关论文
共 21 条
[1]   Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling [J].
Ausems, MGEM ;
Verbiest, J ;
Hermans, MMP ;
Kroos, MA ;
Beemer, FA ;
Wokke, JHJ ;
Sandkuijl, LA ;
Reuser, AJJ ;
van der Ploeg, AT .
EUROPEAN JOURNAL OF HUMAN GENETICS, 1999, 7 (06) :713-716
[2]   Pain assessment: the advantages of using pain scales in lysosomal storage diseases [J].
Cleeland, CS .
ACTA PAEDIATRICA, 2002, 91 :43-47
[3]  
DISANTAGNESE PA, 1950, PEDIATRICS, V6, P607
[4]   GLYCOGEN-STORAGE DISEASE OF MYOCARDIUM WITH OBSTRUCTION TO LEFT VENTRICULAR OUTFLOW [J].
EHLERS, KH ;
ENGLE, MA ;
REDO, SF ;
HAGSTROM, JW ;
LUKAS, DS .
CIRCULATION, 1962, 25 (01) :96-+
[5]  
Engel AG, 1994, MYOLOGY BASIC CLIN, P1533
[6]  
Hirschhorn R., 2001, METABOLIC MOL BASES, P3389
[7]   Pompe disease in infants and children [J].
Kishnani, PS ;
Howell, RR .
JOURNAL OF PEDIATRICS, 2004, 144 (05) :S35-S43
[8]   THE FATIGUE SEVERITY SCALE - APPLICATION TO PATIENTS WITH MULTIPLE-SCLEROSIS AND SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
KRUPP, LB ;
LAROCCA, NG ;
MUIRNASH, J ;
STEINBERG, AD .
ARCHIVES OF NEUROLOGY, 1989, 46 (10) :1121-1123
[9]   Juvenile and adult-onset acid maltase deficiency in France -: Genotype-phenotype correlation [J].
Laforêt, P ;
Nicolino, M ;
Eymard, B ;
Puech, JP ;
Caillaud, C ;
Poenaru, L ;
Fardeau, M .
NEUROLOGY, 2000, 55 (08) :1122-1128
[10]  
Martiniuk F, 1998, AM J MED GENET, V79, P69, DOI 10.1002/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO